News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Alkon Daniel L.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/20/2022 |
4
| Alkon Daniel L. (President and CSO) has filed a Form 4 on Synaptogenix, Inc.|
Txns:
| Sold 19,688 shares
@ $1.1719, valued at
$23.1k
|
|
| 12/01/2022 |
4/A
| Alkon Daniel L. (President and CSO) has filed a Form 4 on Synaptogenix, Inc.|
Txns:
| Granted 43,750 shares
@ $0 |
|
| 12/01/2022 |
4/A
| Alkon Daniel L. (See Remark) has filed a Form 4 on Synaptogenix, Inc.|
Txns:
| Granted 75,000 options to buy
@ $6.07, valued at
$455.3k
|
|
| 11/17/2022 |
4
| Alkon Daniel L. (See Remarks) has filed a Form 4 on Synaptogenix, Inc.|
Txns:
| Granted 112,000 options to buy
@ $6.07, valued at
$679.8k
|
|
| 07/15/2021 |
4
| Alkon Daniel L. (See Remarks) has filed a Form 4 on Synaptogenix, Inc.|
Txns:
| Granted 80,000 shares
@ $0 |
|
| 06/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/14/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/03/2020 |
4
| Alkon Daniel L. (See Remarks) has filed a Form 4 on Neurotrope, Inc.|
Txns:
| Disposed/sold 29,688 shares
@ $0
Disposed/sold 5,469 options to buy
@ $56, valued at
$306.3k
Disposed/sold 124,274 options to buy
@ $10.56, valued at
$1.3M
Disposed/sold 167,000 options to buy
@ $19.62, valued at
$3.3M
Disposed/sold 150,000 options to buy
@ $3.93, valued at
$589.5k
Disposed/sold 40,000 options to buy
@ $0.972, valued at
$38.9k
|
|
| 11/27/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/24/2019 |
4
| Alkon Daniel L. (See Remarks) has filed a Form 4 on Neurotrope, Inc.|
Txns:
| Granted 150,000 options to buy
@ $3.93, valued at
$589.5k
|
|
| 04/13/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/23/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 09/30/2016 |
3
| Alkon Daniel L. (President) has filed a Form 3 on Neurotrope, Inc. |
|
|